Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® ...
Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for patients with all genetic ...
The Phase 1/2 FUNCTION-DMD study will enroll ambulatory patients and is designed to evaluate safety, tolerability, and efficacy, including dystrophin protein expression and functional outcomes. "The ...
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.
~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE)-- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory ...
Amazon S3 on MSN
Measles emergency: 1,748 confirmed cases in 33 states — America on the brink of losing elimination status
The measles emergency in the United States has escalated to 1,748 verified cases across 33 states, with Spartanburg County in ...
1d
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results